DURECT CorpDRRX
DRRX
About: Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
Employees: 14
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
3% more capital invested
Capital invested by funds: $5.12M [Q4 2024] → $5.27M (+$153K) [Q1 2025]
0.81% less ownership
Funds ownership: 21.99% [Q4 2024] → 21.18% (-0.81%) [Q1 2025]
12% less funds holding
Funds holding: 43 [Q4 2024] → 38 (-5) [Q1 2025]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for DRRX.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif. , May 13, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update.
Neutral
Seeking Alpha
2 months ago
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Negative
Zacks Investment Research
2 months ago
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.
Neutral
PRNewsWire
2 months ago
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif.
Neutral
PRNewsWire
2 months ago
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025.
Neutral
PRNewsWire
4 months ago
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
Neutral
PRNewsWire
4 months ago
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence.
Positive
Zacks Investment Research
4 months ago
Durect (DRRX) Upgraded to Strong Buy: Here's Why
Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
5 months ago
New Strong Buy Stocks for January 9th
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Positive
Zacks Investment Research
6 months ago
Durect (DRRX) Upgraded to Buy: Here's What You Should Know
Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™